Langerhans cells are negative regulators of the anti-Leishmania response

Journal of Experimental Medicine

Volumn 208, Issue 5, 2011, Pages 885-891

  Kautz Neu, Kordula ^a   Noordegraaf, Madelon ^b   Dinges, Stephanie ^a   Bennett, Clare L ^c   John, Dominik ^a   Clausen, Björn E ^b   von Stebut, Esther ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; LANGERHANS CELL; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; IMMUNE TOLERANCE; INTERFERON-GAMMA; LANGERHANS CELLS; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 79956067743     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20102318     Document Type: Article

References (30)

1. Ahuja, S.S., R.L. Reddick, N. Sato, E. Montalbo, V. Kostecki, W. Zhao, M.J. Dolan, P.C. Melby, and S.K. Ahuja. 1999. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163:3890-3897.
2. Belkaid, Y., S. Mendez, R. Lira, N. Kadambi, G. Milon, and D. Sacks. 2000. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165:969-977.
3. Belkaid, Y., K.F. Hoffmann, S. Mendez, S. Kamhawi, M.C. Udey, T.A. Wynn, and D.L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:1497-1506.
4. + regulatory T cells control Leishmania major persistence and immunity. Nature. 420:502-507.
5. Bennett, C.L., and B.E. Clausen. 2007. DC ablation in mice: promises, pitfalls, and challenges. Trends Immunol. 28:525-531.
6. Bennett, C.L., E. van Rijn, S. Jung, K. Inaba, R.M. Steinman, M.L. Kapsenberg, and B.E. Clausen. 2005. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J. Cell Biol. 169:569-576.
7. Bennett, C.L., M. Noordegraaf, C.A. Martina, and B.E. Clausen. 2007. Langerhans cells are required for efficient presentation of topically applied hapten to T cells. J. Immunol. 179:6830-6835.
8. Berberich, C., J.R. Ramírez-Pineda, C. Hambrecht, G. Alber, Y.A. Skeiky, and H. Moll. 2003. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J. Immunol. 170:3171-3179.
9. + T cells in experimental leishmaniasis is initiated by different dendritic cell subtypes. J. Immunol. 182:774-783.
10. + dendritic cells. J. Exp. Med. 204:3147-3156.
11. Douillard, P., P. Stoitzner, C.H. Tripp, V. Clair-Moninot, S. Aït-Yahia, A.D. McLellan, A. Eggert, N. Romani, and S. Saeland. 2005. Mouse lymphoid tissue contains distinct subsets of langerin/CD207 dendritic cells, only one of which represents epidermal-derived Langerhans cells. J. Invest. Dermatol. 125:983-994.
12. + dendritic cells survey the skin in the steady state. J. Exp. Med. 204:3133-3146.
13. + dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J. Exp. Med. 207:189-206.
14. Iezzi, G., A. Fröhlich, B. Ernst, F. Ampenberger, S. Saeland, N. Glaichenhaus, and M. Kopf. 2006. Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. J. Immunol. 177:1250-1256.
15. Kaplan, D.H., A. Kissenpfennig, and B.E. Clausen. 2008. Insights into Langerhans cell function from Langerhans cell ablation models. Eur. J. Immunol. 38:2369-2376.
16. Kissenpfennig, A., S. Henri, B. Dubois, C. Laplace-Builhé, P. Perrin, N. Romani, C.H. Tripp, P. Douillard, L. Leserman, D. Kaiserlian, et al. 2005.Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity. 22:643-654.
17. León, B., M. López-Bravo, and C. Ardavín. 2007. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity. 26:519-531.
18. + regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J. Exp. Med. 200:201-210.
19. Misslitz, A.C., K. Bonhagen, D. Harbecke, C. Lippuner, T. Kamradt, and T. Aebischer. 2004. Two waves of antigen-containing dendritic cells in vivo in experimental Leishmania major infection. Eur. J. Immunol. 34:715-725.
20. Moll, H., H. Fuchs, C. Blank, and M. Röllinghoff. 1993. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur. J. Immunol. 23:1595-1601.
21. Nagao, K., F. Ginhoux, W.W. Leitner, S. Motegi, C.L. Bennett, B.E. Clausen, M. Merad, and M.C. Udey. 2009. Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc. Natl. Acad. Sci. USA. 106:3312-3317.
22. + dermal dendritic cells in contact hypersensitivity. J. Invest. Dermatol. 130:2752-2759.
23. + dendritic cells that develop and function independently of epidermal Langerhans cells. J. Exp. Med. 204:3119-3131.
24. Ritter, U., A. Meissner, C. Scheidig, and H. Körner. 2004. CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis. Eur. J. Immunol. 34:1542-550.
25. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858.
26. Takahara, K., Y. Omatsu, Y. Yashima, Y. Maeda, S. Tanaka, T. Iyoda, B.E. Clausen, K. Matsubara, J. Letterio, R.M. Steinman, et al. 2002. Identification and expression of mouse Langerin (CD207) in dendritic cells. Int. Immunol. 14:433-444.
27. Valladeau, J., V. Clair-Moninot, C. Dezutter-Dambuyant, J.J. Pin, A. Kissenpfennig, M.G. Mattéi, S. Ait-Yahia, E.E. Bates, B. Malissen, F. Koch, et al. 2002. Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J. Immunol. 168:782-792.
28. von Stebut, E., Y. Belkaid, T. Jakob, D.L. Sacks, and M.C. Udey. 1998. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J. Exp. Med. 188:1547-1552.
29. von Stebut, E., J.M. Ehrchen, Y. Belkaid, S.L. Kostka, K. Molle, J. Knop, C. Sunderkotter, and M.C. Udey. 2003. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J. Exp. Med. 198:191-199.
30. + regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203:2451-2460.